inhibitory antibodies have been found in a range of gramnegative infections, 4−7 suggesting that analogous mechanisms may apply to other problematic post-transplant gramnegative infections, including those caused by Burkholderia species.
Acquired von Willebrand syndrome and left ventricular assist devices

To the editor:
Bansal et al 1 demonstrated that the fully magnetically levitated centrifugal-flow HeartMate3 (HM3) left ventricular assist device is associated with greater preservation of the structure of von Willebrand factor (vWF) high molecular weight multimers (HMWM) than the HeartMateII (HMII) mechanical bearing axial-flow pump. 1 The findings confirm our previous work regarding the development of acquired von Willebrand syndrome in patients with ventricular assist device (VAD) and the less distinct loss of the vWF HMWM in patients with HM3 compared with HMII. 2, 3 However, there are some differences. Bansal et al 1 reported that the quantitative values for the vWF antigen and activity decrease from baseline to 90 days but also that the 2 device groups did not differ significantly in that regard. In our study, we demonstrated a decreased vWF:collagen binding/vWF:Antigen ratio in patients with VAD (on Day 1, Day 3, Day 7, Day 30, and Day 90) with a greater reduction in patients with HMII than in HM3 -thus corresponding to the increased loss of vWF HMWM in patients with HMII. 2 Bansal and colleagues did not study the assay using collagen binding capacity. We have previously shown that an in-house assay (using Collagen type I) may be more sensitive to describe quantitative functional changes that accompany the structural changes described in the loss of HMWM of vWF. It is important to employ a sensitive test for these analyses, and this contention is supported by other groups who have described that some collagen preparations are more sensitive to HMWM compared to others. 4 In our study, we also described a platelet defect (storage pool defect), which did not differ between patients with HM3 and HMII, and which may also contribute to the bleeding complications. Therefore, new VADs entailing less shear stress need to be developed to reduce the severity of acquired von Willebrand syndrome and platelet disorder in these patients, so that the bleeding events may be curtailed.
